Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Price

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfaR J Harte, J C Matthews, S M O'Reilly, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1996
Active minimisation of radiation scatter during breast radiotherapy: management implications for young patients with good-prognosis primary neoplasmsR J Epstein, S A Kelly, M Cook, et al.
Physics in Medicine and Biology|October 22, 2010
Development and validation of a variance model for dynamic PET: uses in fitting kinetic data and optimizing the injected activityM D Walker, J C Matthews, M-C Asselin, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 24, 2010
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancerA S N Jackson, P Jain, G R Watkins, et al.
British Journal of Cancer|December 21, 2006
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomasE A Griffiths, S A Pritchard, H R Valentine, et al.
Cancer Research|June 1, 1997
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trialsS Osman, S K Luthra, F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomographyA Saleem, R J Harte, J C Matthews, et al.
Cancer Research|April 18, 2001
Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analoguesS Osman, G Rowlinson-Busza, S K Luthra, et al.
British Journal of Cancer|July 1, 2010
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapyS J Lunt, C Cawthorne, M Ali, et al.
Structural Dynamics (Melville, N.Y.)|September 28, 2019
Electrostatic subframing and compressive-sensing video in transmission electron microscopyB W Reed, A A Moghadam, R S Bloom, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfaR J Harte, J C Matthews, S M O'Reilly, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 1, 1996
Active minimisation of radiation scatter during breast radiotherapy: management implications for young patients with good-prognosis primary neoplasmsR J Epstein, S A Kelly, M Cook, et al.
Physics in Medicine and Biology|October 22, 2010
Development and validation of a variance model for dynamic PET: uses in fitting kinetic data and optimizing the injected activityM D Walker, J C Matthews, M-C Asselin, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 24, 2010
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancerA S N Jackson, P Jain, G R Watkins, et al.
British Journal of Cancer|December 21, 2006
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomasE A Griffiths, S A Pritchard, H R Valentine, et al.
Cancer Research|June 1, 1997
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trialsS Osman, S K Luthra, F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomographyA Saleem, R J Harte, J C Matthews, et al.
Cancer Research|April 18, 2001
Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analoguesS Osman, G Rowlinson-Busza, S K Luthra, et al.
British Journal of Cancer|July 1, 2010
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapyS J Lunt, C Cawthorne, M Ali, et al.
Structural Dynamics (Melville, N.Y.)|September 28, 2019
Electrostatic subframing and compressive-sensing video in transmission electron microscopyB W Reed, A A Moghadam, R S Bloom, et al.
Pageof 8